Nicotine pouches, evidence and proportion

The language of crisis should be tested against the scale and direction of the available data. The 2025 National Drug Strategy Household Survey reports that daily smoking among Australians aged 14 and over fell to 5.6%, down from 8.3% in 2022–2023 and 19.5% in 2001. Past-year use of any nicotine product also fell to a historic low of 15.2%. Nicotine pouch use was reported by 1.8% of people aged 14 and over in the past year, although use was higher among adults aged 18–24.

These figures justify monitoring, age controls and proportionate safeguards. They do not, by themselves, establish that nicotine pouches are driving a national health crisis. The principal source of tobacco-related death and disease remains combustible smoking. Public-health language should preserve that distinction so that the response matches the magnitude and nature of the risk.

Nicotine strength is relevant to dependence, adverse effects and safe product design, but nicotine dose alone is not a complete measure of health risk. The central toxicological comparator is combustion. Cigarette smoke exposes users to a complex mixture of toxic and carcinogenic substances generated by burning tobacco; nicotine pouches do not involve combustion.

A proportionate response would set enforceable limits on nicotine per pouch, require accurate labelling, child-resistant packaging, ingredient controls and adverse-event monitoring. It would not assume that every product delivering more nicotine than a single cigarette is therefore as harmful as smoking. Product strength can be regulated directly; comparative risk should be assessed across the whole exposure profile.

That status matters legally, but it should not be presented as a substitute for a comparative-risk assessment. “Not on the ARTG” means that a product has not been registered through Australia’s therapeutic-goods pathway. It does not, by itself, establish that the product is as hazardous as smoking or incapable of reducing harm for an adult who switches completely.

The evidence question and the regulatory-classification question are related but distinct. Australia can require evidence and quality standards without implying that absence from a pharmaceutical register is itself a toxicological verdict. A clearer public explanation would separate legal approval, cessation claims, product safety and relative risk.

Long-term, product-specific evidence is still developing, and uncertainty should be stated plainly. But evidence should be weighed in layers. Clinical and pharmacokinetic studies can inform nicotine delivery and short-term effects. Chemical analyses can compare toxicant profiles. Observational studies can identify patterns of switching, dual use and uptake. Evidence from related oral nicotine products can inform—but not conclusively determine—long-term expectations.

The absence of decades of epidemiology for a newer product does not mean there is no usable evidence. Nor should weaker forms of evidence be used selectively: precautionary concerns, expert opinion and projections should not automatically outweigh direct chemical, pharmacological and population data. The defensible position is calibrated uncertainty—not certainty of safety, but also not certainty of equivalence with smoking.

A policy assessment that excludes the smoking comparator is incomplete. Nicotine pouches are not risk-free, and non-users—especially young people—should not start using them. For adults who smoke, however, the relevant question is whether complete substitution is likely to reduce exposure to the toxic products of combustion.

European risk assessments and peer-reviewed toxicological studies generally identify substantially fewer and lower levels of many harmful constituents in nicotine pouches than in cigarettes, while also identifying risks from nicotine exposure and product variability. This supports regulated risk differentiation, not unrestricted sale. Public communication should be capable of saying both things at once: pouches carry risks, and smoking is far more dangerous.

The 18–24 result warrants attention, particularly because first-time measurement limits trend analysis. But 18–24-year-olds are adults, and past-year use is not the same as daily or dependent use. The same survey reports that current e-cigarette use among this age group fell from 20.6% to 14.0%, current smoking fell to 6.1%, and overall past-year nicotine use fell from 30.7% to 24.4%.

This does not remove concern about youth or young-adult uptake. It does show why product-specific prevalence should be interpreted alongside total nicotine use, frequency of use and displacement of smoking. The aim should be to prevent initiation among non-users while preserving incentives for smokers to move away from combustion.

Removing physician-mediated access may reduce one route to unapproved products, but policy analysis should also examine what happens next. Demand may not disappear. Some consumers may return to cigarettes, purchase through informal sellers or import products from sources without reliable strength limits, ingredient controls or child-resistant packaging.

These outcomes are not inevitable, but they are foreseeable enough to require an impact assessment. A policy that closes regulated or supervised routes while leaving cigarettes widely available risks preserving the easiest access to the highest-risk nicotine product. Enforcement should be paired with a lawful, standards-based pathway if the objective is both consumer protection and smoking harm reduction.

Youth-targeted marketing, misleading therapeutic claims and irresponsible promotion should be prohibited. That does not require suppressing every scientifically supportable comparison with smoking. Consumers can be told that a product is not harmless, is addictive, is not approved as a cessation medicine, and is likely to expose a complete switcher to substantially fewer combustion-related toxicants than cigarettes.

The distinction matters. Marketing regulation should control audience, placement, descriptors, claims and evidence standards. It should not force all nicotine products into a single undifferentiated risk category. Accurate comparative information can support informed adult choice while strict controls protect young people.

Several of those measures are compatible with a risk-based framework. The question is whether enforcement is combined with a viable legal market for compliant adult products.

A proportionate model would maintain strict age restrictions and meaningful penalties for sales to minors; prohibit youth-oriented branding and unsupported health claims; set maximum nicotine content per pouch; require ingredient disclosure, contaminant limits, prominent warnings and child-resistant packaging; license importers and retailers; collect adverse-event and market data; and periodically review population outcomes.

This approach would not treat nicotine pouches as harmless or as approved medicines. It would regulate them according to their actual characteristics, preserve the cigarette as the highest-risk comparator and reduce incentives for illicit supply.